A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. - Wikidata - wikimedia - TriplyDB

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

http://www.wikidata.org/entity/Q39342652

about

Optimizing tumor immune response through combination of radiation and immunotherapy.Should we be combining local tumor therapies with immunotherapies as standard?Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.Improving radiotherapy in cancer treatment: Promises and challenges.CyTOF Measurement of Immunocompetence Across Major Immune Cell Types.Radiation effects on antitumor immune responses: current perspectives and challenges.Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.Drastic effect on giant lung metastatic melanoma by sequential administration of nivolumab with ipilimumab/radiation combination therapy.Propofol promotes apoptosis and suppresses the HOTAIR-mediated mTOR/p70S6K signaling pathway in melanoma cells.Phase I Trial: SABR and Ipilimumab-Response.Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.Radiotherapy and checkpoint inhibitors: a winning new combination?In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.Melanoma Immunotherapy: Next-Generation Biomarkers.Effects of radiation on the metastatic process.Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.Role of noninvasive molecular imaging in determining response Toxicity of radiation and immunotherapy combinations Exploring optimal sequencing of radiation and immunotherapy combinations Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy

P2860

Q38614781-24EA4562-08B0-4AD7-9E07-D0AF3F41A88E Q38638858-864C3578-56E1-4865-A824-0E6A2181562C Q39099114-B227C175-8A9B-4C52-BD9D-27DB9BC06715 Q41899048-72966E05-E074-48B8-B7C7-1956730E96A3 Q45930699-2ECC8725-FC95-4B46-AE36-967E996DD0A4 Q47703452-BDE3A3AC-0CEB-4DBA-98A1-F9CB552DE45A Q47899811-7542DA44-7EFB-4A04-B8D3-80C0B0BBCD51 Q48239978-25268B49-B1AE-4770-80C0-D146B1A893F7 Q49280976-1EE40437-BD7B-4AC8-AA38-34E76BFFCC1D Q50274659-F0ECDEA9-7399-456C-B25B-F869A5CB7A91 Q50532335-C18106AA-3354-4724-A423-E696F6D1F0E4 Q52584384-71C37EBB-5132-407F-AECC-A7FB58544394 Q55106579-A954A4A9-CCFB-429F-9DD3-037E309FCEF1 Q55156734-D77B2311-A086-40FD-BC26-6ED32406F8DF Q55417312-275FD97E-9B79-430A-A88F-A4D3F2610911 Q55491553-BF11EA73-90C5-4AFE-9E32-6A32C715EC99 Q58119177-435B7E75-C069-4036-91D4-061F5CB6D591 Q58119196-6DBFE23A-65D8-4233-97BE-001D262D0684 Q58119202-422A0FA4-B194-419D-BFD6-385190F61A32 Q58119207-B7BD56C7-693C-40F4-90A6-E6D0299C979C Q58767976-BF669F23-34AA-46EF-81D8-263A66F9BE97 Q58791220-2D4E4781-724A-40BB-A01A-49EDC7CE1DF4

P2860

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

http://www.wikidata.org/entity/Q39342652

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@en

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@nl

type

label

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@en

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@nl

prefLabel

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@en

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@nl

P1433

Q39342652-D9A278F4-E568-42F1-B5EE-6C3EA8A2DBB9

P1476

Q39342652-4E5D5F68-1840-4122-91A5-03040522DB24

P2093

Q39342652-25C836CA-1982-4417-A550-C1D38D9ACC26

Q39342652-2759CE45-078D-48F2-A736-8C24148FBFC4

Q39342652-3A827F7D-D642-4E8A-BEC5-C08EDADA5C23

Q39342652-52FCB884-778E-4546-A63D-8577AABBF4E5

Q39342652-6CA16F72-BB57-4E8A-91E6-3E36F5DA5114

Q39342652-9CF4EB79-D0E2-4509-8CAE-B2276FF2AF12

Q39342652-CA0C65BD-AEDD-4EEC-AB9D-B47BC5E1BF69

Q39342652-DCEAFB37-E905-4BC1-8259-2319BEADA030

Q39342652-EF933C76-9F60-4F08-929C-AEC7370639F6

P2860

Q39342652-001512CB-60AB-47FC-B79B-30FD46B68DDD

Q39342652-0DF06D64-B7FC-482F-9CD5-8F53291561A3

Q39342652-12E11E33-C277-47DE-822D-B0EA8E2B1192

Q39342652-13660B2A-72E1-4E2C-98FD-4CE709141A34

Q39342652-220121AA-607D-4F7C-88A8-851BFF5B55C9

Q39342652-4BBB412E-0BE3-4A3F-B1CB-9734FC3C0028

Q39342652-4FDC3448-9618-4673-8EC5-659B1E307C11

Q39342652-6B18E064-8390-48E9-BA89-9D6432A3B3AA

Q39342652-6F159FF2-C07F-43FC-BDE9-D2F8DC04F25A

Q39342652-A7DA49F3-D763-4B19-917D-88844C82AD15

P304

Q39342652-00CC8F87-145D-412A-AEC7-A5AF15420E7B

P31

Q39342652-27E63185-4750-4DDF-982E-0C610F2A7B65

P356

Q39342652-8FA55774-0685-42F9-AE0F-C0AC77E6B45F

P407

Q39342652-68D59596-0566-4EDF-AD58-FFAD8E042E91

P433

Q39342652-3C1060CD-7975-44F9-B3AD-80F79DF21A4A

P478

Q39342652-94C5E476-9702-4C3B-9096-EBB77C73695E

P577

Q39342652-8B2181AC-B3B4-4AF0-B8C5-E03F2FD8D6E3

P698

Q39342652-7B50A754-21FB-466B-A8CC-B306FABEB1F2

P921

Q39342652-714E6D33-B3A6-4E83-8C63-F68971D303D3

Q39342652-9A53F59E-6EF8-474D-B143-8F58FC5D5C16

P932

Q39342652-3DEA1A91-01D2-409C-8B67-FEE140DC9AE4

P356

J.IJROBP.2016.07.005

P1433

International Journal of Radiation Oncology Biology Physics

P1476

A Prospective Clinical Trial C ...... herapy in Metastatic Melanoma.

@en

P2093

Holden T Maecker

http://www.w3.org/2001/XMLSchema#string

Lei Shura

http://www.w3.org/2001/XMLSchema#string

Priyanka B Subrahmanyam

http://www.w3.org/2001/XMLSchema#string

Saurabh Saha

http://www.w3.org/2001/XMLSchema#string

Sunil A Reddy

http://www.w3.org/2001/XMLSchema#string

Susan J Knox

http://www.w3.org/2001/XMLSchema#string

Susan M Hiniker

http://www.w3.org/2001/XMLSchema#string

Susan M Swetter

http://www.w3.org/2001/XMLSchema#string

Yael Rosenberg-Hasson

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Immunologic correlates of the abscopal effect in a patient with melanoma

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

P304

578-588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2016.07.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27681753

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5077166

http://www.w3.org/2001/XMLSchema#string